Teva Pharmaceutical Industries (TEVA) Cost of Revenue (2016 - 2026)

Teva Pharmaceutical Industries' Cost of Revenue history runs 11 years deep, the most recent figure standing at $2.0 billion for Q1 2026.

• Quarterly Cost of Revenue changed 0.15% year-over-year to $2.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.3 billion (down 1.53% YoY) and the FY2025 annual result came in at $8.3 billion, down 1.9% from the prior year.
• Cost of Revenue was $2.0 billion for Q1 2026 at Teva Pharmaceutical Industries, down from $2.1 billion in the prior quarter.
• Across five years, Cost of Revenue topped out at $2.2 billion in Q3 2024 and bottomed at $1.9 billion in Q1 2022.
• A 5-year average of $2.1 billion and a median of $2.1 billion in 2025 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2022 — Cost of Revenue decreased 8.7% — and 2024, when it rose 9.2%.
• Teva Pharmaceutical Industries' Cost of Revenue stood at $2.1 billion in 2022, then retreated by 3.41% to $2.0 billion in 2023, then increased by 3.33% to $2.1 billion in 2024, then fell by 2.51% to $2.1 billion in 2025, then decreased by 2.19% to $2.0 billion in 2026.
• Business Quant data shows TEVA's Cost of Revenue at $2.0 billion in Q1 2026, $2.1 billion in Q4 2025, and $2.2 billion in Q3 2025.